Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 166 AL 180

Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

Collins EC, Lu M, Beck R, Hendrix J, Hodsdon ME, Hansson O.

Alzheimers Dement. 2026 Aug;22(8):e71740. doi: 10.1002/alz.71740.

Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility

Hazan J, Salemme S, Liu KY, Howard R.

Neurology. 2026 Sep 8;107(5):e218403. doi: 10.1212/WNL.0000000000218403. Epub 2026 Aug 12.

Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants

Piura YD, Aduen PA, Schecter L, Jain MK, Algeciras-Schimnich A, Figdore DJ, Bornhorst J, Petersen RC, Jr CRJ, Graff-Radford NR, Lachner C, Day GS.

Alzheimers Dement. 2026 Aug;22(8):e71763. doi: 10.1002/alz.71763.

Exosome-derived biomarkers as non-invasive tools in stroke, Parkinson's disease, and Alzheimer's disease

Talebi A, Nabili S, Alaei M, Koohsarian P, Doostmohammadi A, Dadashpour M.

Metab Brain Dis. 2026 Aug 20;41(1):189. doi: 10.1007/s11011-026-01947-0.

Mapping the neurovascular landscape in aging and dementia: cerebral small vessel disease markers in a multicenter Latin American cohort

Altschuler F, Castro-Laguardia AM, Canziani V, O'Byrne DF, Hazelton J, Migeot J, Maito M, García AM, Bruno MA, Magrath N, Slachevsky A, Behrens MI, Custodio N, Ávila-Funes JA, Matallana D, Aguillón D, Santamaria-García H, Resende E, Takada L, Brusco LI, Yokoyama JS, Miller B, Ibáñez A, Medel V, Campo CG.

Alzheimers Dement. 2026 May;22(5):e71468. doi: 10.1002/alz.71468.

Leading by example: How the Webster team's systematic review quietly rebuked the field's preoccupation with biomarker "disclosure," and why it matters

Lingler JH.

J Alzheimers Dis. 2026 Mar;110(1):86-88. doi: 10.1177/13872877251412917. Epub 2026 Feb 13.

Decreased interleukin-8 levels in the peripheral blood of Alzheimer's disease patients

Ros F, Martínez Lozano MD, Arnau J, Martínez J, Vericat A, Sánchez R, Burgos JS.

J Alzheimers Dis. 2026 Apr;110(4):1778-1792. doi: 10.1177/13872877261428052. Epub 2026 Mar 10.

Comparison Study of Different Feature Selection Techniques for the Diagnosis of Alzheimer's Disease

Masood F, Al-Hyari A, Al-Wajidi W; Alzheimer’s Disease Neuroimaging Initiative.

Am J Alzheimers Dis Other Demen. 2026 Jan-Dec;41:15333175261418472. doi: 10.1177/15333175261418472. Epub 2026 Jan 19.

Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study

Brem AK, Khan Z, Radermacher J, Georgiadis K, Lazarou I, Grammatikopoulou M, Pickering E, Mitterreiter J, Aakre JA, Ashton NJ, Baquero M, Beser-Robles M, Braboszcz C, Brandt S, Brown J, Cacciamani F, Campill S, Collins C, Deshpande P, Diaz A, Durrleman S, Engelborghs S, Ferré-González L, Frisoni GB, Gjestsen MT, Gove D, Honigberg L, Huang B, Hudak A, Kaushik S, Letoha T, Marquardt G, Mendes AJ, Müllenborn M, Paletta L, de Barros NP, Pszeida M, Vik-Mo AO, Rostamipour H, Perneczky R, Rauchmann BS, Russegger S, Schirmer T, Shadmaan A, Solana AB, Soria-Frisch A, Tegethoff P, Ribbens A, De Witte S, van der Giezen M, Nikolopoulos S, Corbett A, Fröhlich H, Aarsland D; PREDICTOM Consortium.

J Prev Alzheimers Dis. 2026 May;13(5):100545. doi: 10.1016/j.tjpad.2026.100545. Epub 2026 Mar 26.

The Alzheimer's Pathways Sleep Study (ALPS): an experimental randomized controlled trial to improve cognition and Alzheimer's pathophysiology through slow-wave sleep

Dong YC, Habte RF, Dessa KM, Fletcher ME, Ianni AM, Lopresti BJ, Aizenstein HJ, Cohen AD, Karikari TK, Weinstein AM, Gebara MA, Wallace ML, Buysse DJ, Wilckens KA.

Trials. 2026 Feb 19;27(1):237. doi: 10.1186/s13063-026-09505-w.

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease

Cetindag AC, Schipke CG, Esselmann H, Kruse N, Wiltfang J, Schneider A, Fliessbach K, Miklitz C, Maier F, Buerger K, Janowitz D, Ewers M, Stöcklein S, Perneczky R, Rauchmann BS, Kurz C, Teipel S, Kilimann I, Goerss D, Laske C, Sodenkamp S, Najafpour E, Wagner M, Roeske S, Frommann I, Stark M, Brosseron F, Ramirez A, Kleineidam L, Priller J, Spruth EJ, Gemenetzi M, Altenstein S, Düzel E, Glanz W, Incesoy EI, Butryn M, Bauer C, Jessen F, Peters O.

J Prev Alzheimers Dis. 2026 May;13(5):100544. doi: 10.1016/j.tjpad.2026.100544. Epub 2026 Mar 28.

What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?

Hazan J, Liu KY, Isaacs JD, Fox NC, Howard R.

Neurology. 2026 May 26;106(10):e214953. doi: 10.1212/WNL.0000000000214953. Epub 2026 May 4.

Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort

Landau SM, Liu P, Harrison TM, Taggett J, Ward TJ, Murphy A, Lockhart SN, Lovato LC, Koeppe R, Farias ST, Papp KV, Snyder HM, Harvey DJ, Espeland M, Maillard P, DeCarli C, Vemuri P, Weiner M, Baker LD, Jagust WJ; U.S. POINTER Study Group and Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2026 May;22(5):e71472. doi: 10.1002/alz.71472.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias